Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

CombiVacS, 2021 NCT04860739

heterologous prime-boost (n=450) vs. control (n=226)

randomized controlled trial   risk of bias NA

Studied treatment

BNT162b2 (0·3 mL) via a single intramuscular injection
BNT162b2 (Comirnaty) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria) 50-84 days before

Control treatment

continue observation
only one dose of ChAdOx1-S (Vaxzevria)

Patients

COVID-19 prophylaxis (excluding children)

Method

open-label

five university hospitals in Spain

Remark